Effect of Deregulation of the Brazilian National Controlled Products Management System on Antidepressants' Sales Data Deregulation of a Brazilian Drug Electronic System
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Vanessa Gomes Lima und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Universidade Estadual de Campinas, São Paulo, Brazil. Hauptthemen laut MEDLINE: Antidepressive Agents, Commerce, Drug and Narcotic Control. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP).
Abstract (Originalsprache)
Purpose
To assess the effect of deregulating the national sales reporting system on Brazilian pharmacoepidemiologic data on antidepressants.
Methods
This was a time series analysis to assess the trends in antidepressant sales in Brazilian drugstores from January 2014 to December 2022 using the Brazilian National Controlled Products Management System (SNGPC) and to predict sales records for 2022 after the deregulation of the mandatory record in December 2021. Antidepressant sales were converted to defined daily doses per 1000 inhabitants per day (DID). The seasonal autoregressive integrated moving average (SARIMA) was used to predict sales records for 2022. All analyses were conducted in Stata v.14.2.
Results
Sales of patients taking antidepressants increased significantly from 2014 (mean: 14.7 DID/month) to 2020 (mean: 33.5 DID/month; β = 0.231; p < 0.001). After the start of the COVID‐19 pandemic, the increasing trend continued, but the change was not significant ( β = 0.330; p = 0.130). After the deregulation, a sharp decrease was observed ( β = −1.032; p < 0.001). The monthly antidepressant sales forecasted for 2022 were 36.5 DID, while the observed value was 2.5 DID.
Conclusion
Deregulation of SNGPC registration significantly decreased the number of antidepressant sales records. This measure affected the availability of pharmacoepidemiological data and research in Brazil.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Universidade Estadual de Campinas, São Paulo, Brazil.
- Department of Public Health, School of Health Sciences, University of Brasília, Brasília, Brazil.
ORCID-Profile: Taís Freire Galvão
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Zitieren
APA
Lima, V. G., Silva, M. T., Biase, T. M. M. A., & Galvão, T. F. (2025). Effect of Deregulation of the Brazilian National Controlled Products Management System on Antidepressants' Sales Data Deregulation of a Brazilian Drug Electronic System. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70136
Vancouver
Lima VG, Silva MT, Biase TMMA, Galvão TF. Effect of Deregulation of the Brazilian National Controlled Products Management System on Antidepressants' Sales Data Deregulation of a Brazilian Drug Electronic System. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70136
BibTeX
@article{Lima2025,
author = {Lima, Vanessa Gomes and Silva, Marcus Tolentino and Biase, Tayanny Margarida Menezes Almeida and Galvão, Taís Freire},
title = {Effect of Deregulation of the Brazilian National Controlled Products Management System on Antidepressants' Sales Data Deregulation of a Brazilian Drug Electronic System},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70136}
}
EUVIMED